0
Upcoming Allied Market Research
2023
Bio-defense Market

Bio-defense Market: Global Opportunity Analysis and Industry Forecast 2023-2030 Market

Report Code: A08413
Nov 2023 | Pages: NA
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Bio-defense Market

Request Now !

Bio-defense accounts for the use of various medical procedures that help in protecting individuals against bioterrorism, which involves not only drugs and vaccinations but also research and various health preparations for the population for defending themselves against such biological attacks. Bio-defenses are a combination of different systems and processes, which are put together in a place by bioscience laboratories, agricultural managers, customs agents, and other professionals to prevent the use of dangerous pathogens and toxins. Examples of these include the regulations that are imposed on the research carried out on certain pathogens, or preparatory plans for the case of a hostile disease outbreak. To build and maintain a successful bio-defense system, laboratories should have a mechanism methodology for the investigation of the outbreak and also a mechanism to prevent a biological attack. This mechanism should comprise primitive, secondary, and tertiary level prevention from the biological attacks.

Biodefense

COVID-19 scenario analysis:

  • Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19. 
  • Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs as many developed countries are short of these drugs. The pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19.
  • Attributed to such factors, COVID-19 is expected to have a significant impact on the market.

Top impacting factors: Market scenario analysis, trends, drivers, and impact analysis

Governments are taking various initiatives to enhance the readiness against chemical, biological, nuclear and radiological threats, advancements, and adoption through the technological perspective, gene chips being produced for pathogen detection in forensic division, database management systems, nanotechnology, and advanced detector hardware in bio-defense drug development. These are the major factors affecting the bio-defense market positively.

There has been a rise in the frequency of infectious diseases, such as influenza, that has spread a lot of awareness and encouraged pharmaceutical companies to work on R&D for such biological threats. Various programs are also conducted to improvise the scientific research of infectious diseases and create awareness within the public and encourage the population to use public health and be prepared for such biological attacks.

Additionally, the congenital Zika virus infection incidence has helped to boost the investments in the field of bio-defense. Nuclear or radiation weapons are capable of destruction due to their harmful effects, such as radiations, and cause damage equivalent to explosive bombs. To reduce the risk of bio attacks, governments across the world provide funding for medical countermeasures against the attacks to help the market growth positively. Moreover, there has been significant growth in the investments by governments in R&D in North America & European countries. Governments of the Asia-Pacific and Latin American countries are also working on new and favorable initiatives to develop their bio-defense systems. The upgrades in the technological aspect in the biotechnology sector in North America and Europe also contributes to the market growth.

On the other hand, the funding provided for manufacturing vaccines against bioterrorism attacks by authorities in developing and underdeveloped economies is considerably low and hampers the bio-defense market growth.

New product launches and acquisitions to boost the market

On August 8th, 2018, Emergent BioSolutions, Inc. took possession of PaxVax Holding Company Ltd., a developer and manufacturer of vaccines to fight against infectious diseases. In 2018, the U.S. government announced National Bio-defense Strategy and Implementation Plan, the National Defense Strategy, and the National Counterterrorism Strategy, the National Security Strategy, and the National Counter WMD Strategy to provide bio-defense and bio-security to the country. On January 27th, 2017, Emergent BioSolutions Inc. got an approval from the German Federal Ministry of Health, which allowed it to market BioThrax, which was an Anthrax vaccine.

Surge in usage in government and military applications

The major consumers of the bio-defense market are the military and governments of any country. As the governments are closely looking upon the current and future policies and the activities to understand the bio-security and bio-defense threats & preventions, various pharmaceutical companies operating in the bio-defense market have considerable opportunities to expand and be prepared for any bioterrorism.

Key benefits of the report:

  • This study presents the analytical depiction of the bio-defense market along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the bio-defense market share.
  • The current market is quantitatively analyzed to highlight the bio-defense market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the bio-defense market.
  • The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the bio-defense market research report:

  • Which are the leading market players active in the market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What are the projections for the future that would help in taking further strategic steps?
  •  

Bio-defense Market: Global Opportunity Analysis and Industry Forecast 2020–2027 Report Highlights

Aspects Details
By Product
  • Anthrax
  • Small Pox
  • Botulism
  • Radiation/Nuclear
  • Others
By Application
  • Military
  • Civilian
By End Users
  • Government Institutions
  • Military
  • Others
By Region
  • North America  (US, Canada)
  • Europe  (Germany, UK, France, rest of Europe)
  • Asia-Pacific  (China, Japan, India, rest of Asia-Pacific)
  • Latin America  (Brazil, Mexico, rest of LATAM)
  • the Middle East 
  • Africa 
Key Market Players Bavarian Nordic, Elusys Therapeutics, Inc., Xoma Corporation, Dynavax Technologies Corporation, Cleveland Biolabs, Achaogen, Inc., SIGA Technologies, Inc., Alnylam Pharmaceuticals, Inc., PharmAthene, Inc., Emergent Bio-Solutions, Inc., Ichor Medical Systems, Nano therapeutics, Inc., Dynport Vaccine Company LLC
 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: BIO-DEFENSE MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Anthrax

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Small Pox

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Botulism

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Radiation/Nuclear

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: BIO-DEFENSE MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Military

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Civilian

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: BIO-DEFENSE MARKET, BY END USERS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End Users

    • 6.2. Government Institutions

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Military

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: BIO-DEFENSE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By End Users

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Bio-defense Market

        • 7.2.6.1. Market Size and Forecast, By Product
        • 7.2.6.2. Market Size and Forecast, By Application
        • 7.2.6.3. Market Size and Forecast, By End Users
      • 7.2.7. Canada Bio-defense Market

        • 7.2.7.1. Market Size and Forecast, By Product
        • 7.2.7.2. Market Size and Forecast, By Application
        • 7.2.7.3. Market Size and Forecast, By End Users
      • 7.2.8. Mexico Bio-defense Market

        • 7.2.8.1. Market Size and Forecast, By Product
        • 7.2.8.2. Market Size and Forecast, By Application
        • 7.2.8.3. Market Size and Forecast, By End Users
    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By End Users

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Bio-defense Market

        • 7.3.6.1. Market Size and Forecast, By Product
        • 7.3.6.2. Market Size and Forecast, By Application
        • 7.3.6.3. Market Size and Forecast, By End Users
      • 7.3.7. Germany Bio-defense Market

        • 7.3.7.1. Market Size and Forecast, By Product
        • 7.3.7.2. Market Size and Forecast, By Application
        • 7.3.7.3. Market Size and Forecast, By End Users
      • 7.3.8. Italy Bio-defense Market

        • 7.3.8.1. Market Size and Forecast, By Product
        • 7.3.8.2. Market Size and Forecast, By Application
        • 7.3.8.3. Market Size and Forecast, By End Users
      • 7.3.9. Spain Bio-defense Market

        • 7.3.9.1. Market Size and Forecast, By Product
        • 7.3.9.2. Market Size and Forecast, By Application
        • 7.3.9.3. Market Size and Forecast, By End Users
      • 7.3.10. UK Bio-defense Market

        • 7.3.10.1. Market Size and Forecast, By Product
        • 7.3.10.2. Market Size and Forecast, By Application
        • 7.3.10.3. Market Size and Forecast, By End Users
      • 7.3.11. Russia Bio-defense Market

        • 7.3.11.1. Market Size and Forecast, By Product
        • 7.3.11.2. Market Size and Forecast, By Application
        • 7.3.11.3. Market Size and Forecast, By End Users
      • 7.3.12. Rest Of Europe Bio-defense Market

        • 7.3.12.1. Market Size and Forecast, By Product
        • 7.3.12.2. Market Size and Forecast, By Application
        • 7.3.12.3. Market Size and Forecast, By End Users
    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By End Users

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Bio-defense Market

        • 7.4.6.1. Market Size and Forecast, By Product
        • 7.4.6.2. Market Size and Forecast, By Application
        • 7.4.6.3. Market Size and Forecast, By End Users
      • 7.4.7. Japan Bio-defense Market

        • 7.4.7.1. Market Size and Forecast, By Product
        • 7.4.7.2. Market Size and Forecast, By Application
        • 7.4.7.3. Market Size and Forecast, By End Users
      • 7.4.8. India Bio-defense Market

        • 7.4.8.1. Market Size and Forecast, By Product
        • 7.4.8.2. Market Size and Forecast, By Application
        • 7.4.8.3. Market Size and Forecast, By End Users
      • 7.4.9. South Korea Bio-defense Market

        • 7.4.9.1. Market Size and Forecast, By Product
        • 7.4.9.2. Market Size and Forecast, By Application
        • 7.4.9.3. Market Size and Forecast, By End Users
      • 7.4.10. Australia Bio-defense Market

        • 7.4.10.1. Market Size and Forecast, By Product
        • 7.4.10.2. Market Size and Forecast, By Application
        • 7.4.10.3. Market Size and Forecast, By End Users
      • 7.4.11. Thailand Bio-defense Market

        • 7.4.11.1. Market Size and Forecast, By Product
        • 7.4.11.2. Market Size and Forecast, By Application
        • 7.4.11.3. Market Size and Forecast, By End Users
      • 7.4.12. Malaysia Bio-defense Market

        • 7.4.12.1. Market Size and Forecast, By Product
        • 7.4.12.2. Market Size and Forecast, By Application
        • 7.4.12.3. Market Size and Forecast, By End Users
      • 7.4.13. Indonesia Bio-defense Market

        • 7.4.13.1. Market Size and Forecast, By Product
        • 7.4.13.2. Market Size and Forecast, By Application
        • 7.4.13.3. Market Size and Forecast, By End Users
      • 7.4.14. Rest of Asia Pacific Bio-defense Market

        • 7.4.14.1. Market Size and Forecast, By Product
        • 7.4.14.2. Market Size and Forecast, By Application
        • 7.4.14.3. Market Size and Forecast, By End Users
    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By End Users

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Bio-defense Market

        • 7.5.6.1. Market Size and Forecast, By Product
        • 7.5.6.2. Market Size and Forecast, By Application
        • 7.5.6.3. Market Size and Forecast, By End Users
      • 7.5.7. South Africa Bio-defense Market

        • 7.5.7.1. Market Size and Forecast, By Product
        • 7.5.7.2. Market Size and Forecast, By Application
        • 7.5.7.3. Market Size and Forecast, By End Users
      • 7.5.8. Saudi Arabia Bio-defense Market

        • 7.5.8.1. Market Size and Forecast, By Product
        • 7.5.8.2. Market Size and Forecast, By Application
        • 7.5.8.3. Market Size and Forecast, By End Users
      • 7.5.9. UAE Bio-defense Market

        • 7.5.9.1. Market Size and Forecast, By Product
        • 7.5.9.2. Market Size and Forecast, By Application
        • 7.5.9.3. Market Size and Forecast, By End Users
      • 7.5.10. Argentina Bio-defense Market

        • 7.5.10.1. Market Size and Forecast, By Product
        • 7.5.10.2. Market Size and Forecast, By Application
        • 7.5.10.3. Market Size and Forecast, By End Users
      • 7.5.11. Rest of LAMEA Bio-defense Market

        • 7.5.11.1. Market Size and Forecast, By Product
        • 7.5.11.2. Market Size and Forecast, By Application
        • 7.5.11.3. Market Size and Forecast, By End Users
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Emergent Bio-Solutions, Inc.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Xoma Corporation

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. PharmAthene, Inc.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. SIGA Technologies, Inc.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Dynavax Technologies Corporation

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Elusys Therapeutics, Inc.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Cleveland Biolabs

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Ichor Medical Systems

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Dynport Vaccine Company LLC

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Achaogen, Inc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

    • 9.11. Bavarian Nordic

      • 9.11.1. Company Overview

      • 9.11.2. Key Executives

      • 9.11.3. Company Snapshot

      • 9.11.4. Operating Business Segments

      • 9.11.5. Product Portfolio

      • 9.11.6. Business Performance

      • 9.11.7. Key Strategic Moves and Developments

    • 9.12. Nano Therapeutics, Inc.

      • 9.12.1. Company Overview

      • 9.12.2. Key Executives

      • 9.12.3. Company Snapshot

      • 9.12.4. Operating Business Segments

      • 9.12.5. Product Portfolio

      • 9.12.6. Business Performance

      • 9.12.7. Key Strategic Moves and Developments

    • 9.13. Alnylam Pharmaceuticals, Inc.

      • 9.13.1. Company Overview

      • 9.13.2. Key Executives

      • 9.13.3. Company Snapshot

      • 9.13.4. Operating Business Segments

      • 9.13.5. Product Portfolio

      • 9.13.6. Business Performance

      • 9.13.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL BIO-DEFENSE MARKET, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL BIO-DEFENSE MARKET FOR ANTHRAX, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL BIO-DEFENSE MARKET FOR SMALL POX, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL BIO-DEFENSE MARKET FOR BOTULISM, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL BIO-DEFENSE MARKET FOR RADIATION/NUCLEAR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL BIO-DEFENSE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL BIO-DEFENSE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL BIO-DEFENSE MARKET FOR MILITARY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL BIO-DEFENSE MARKET FOR CIVILIAN, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL BIO-DEFENSE MARKET, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL BIO-DEFENSE MARKET FOR GOVERNMENT INSTITUTIONS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL BIO-DEFENSE MARKET FOR MILITARY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL BIO-DEFENSE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL BIO-DEFENSE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA BIO-DEFENSE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. NORTH AMERICA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 20. U.S. BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 21. U.S. BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 23. CANADA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. CANADA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MEXICO BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE BIO-DEFENSE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 31. EUROPE BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 33. FRANCE BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 36. GERMANY BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 37. GERMANY BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 38. ITALY BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 39. ITALY BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. ITALY BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 42. SPAIN BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 44. UK BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 45. UK BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. UK BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 47. RUSSIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 48. RUSSIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. RUSSIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 50. REST OF EUROPE BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 51. REST OF EUROPE BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. REST OF EUROPE BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 53. ASIA-PACIFIC BIO-DEFENSE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 54. ASIA-PACIFIC BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 55. ASIA-PACIFIC BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 56. ASIA-PACIFIC BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 58. CHINA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 59. CHINA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 60. JAPAN BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 61. JAPAN BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 62. JAPAN BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 63. INDIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 64. INDIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. INDIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH KOREA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 69. AUSTRALIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 70. AUSTRALIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. AUSTRALIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 72. THAILAND BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 73. THAILAND BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. THAILAND BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 75. MALAYSIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 76. MALAYSIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. MALAYSIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 78. INDONESIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 79. INDONESIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. INDONESIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 81. REST OF ASIA PACIFIC BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 82. REST OF ASIA PACIFIC BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. REST OF ASIA PACIFIC BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 84. LAMEA BIO-DEFENSE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 85. LAMEA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 86. LAMEA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 87. LAMEA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 88. BRAZIL BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 89. BRAZIL BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 90. BRAZIL BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 91. SOUTH AFRICA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 92. SOUTH AFRICA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. SOUTH AFRICA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 94. SAUDI ARABIA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 95. SAUDI ARABIA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. SAUDI ARABIA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 97. UAE BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 98. UAE BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. UAE BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 100. ARGENTINA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 101. ARGENTINA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. ARGENTINA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 103. REST OF LAMEA BIO-DEFENSE, BY PRODUCT, 2022-2032 ($MILLION)
  • TABLE 104. REST OF LAMEA BIO-DEFENSE, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. REST OF LAMEA BIO-DEFENSE, BY END USERS, 2022-2032 ($MILLION)
  • TABLE 106. EMERGENT BIO-SOLUTIONS, INC.: KEY EXECUTIVES
  • TABLE 107. EMERGENT BIO-SOLUTIONS, INC.: COMPANY SNAPSHOT
  • TABLE 108. EMERGENT BIO-SOLUTIONS, INC.: OPERATING SEGMENTS
  • TABLE 109. EMERGENT BIO-SOLUTIONS, INC.: PRODUCT PORTFOLIO
  • TABLE 110. EMERGENT BIO-SOLUTIONS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. XOMA CORPORATION: KEY EXECUTIVES
  • TABLE 112. XOMA CORPORATION: COMPANY SNAPSHOT
  • TABLE 113. XOMA CORPORATION: OPERATING SEGMENTS
  • TABLE 114. XOMA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 115. XOMA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. PHARMATHENE, INC.: KEY EXECUTIVES
  • TABLE 117. PHARMATHENE, INC.: COMPANY SNAPSHOT
  • TABLE 118. PHARMATHENE, INC.: OPERATING SEGMENTS
  • TABLE 119. PHARMATHENE, INC.: PRODUCT PORTFOLIO
  • TABLE 120. PHARMATHENE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 121. SIGA TECHNOLOGIES, INC.: KEY EXECUTIVES
  • TABLE 122. SIGA TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • TABLE 123. SIGA TECHNOLOGIES, INC.: OPERATING SEGMENTS
  • TABLE 124. SIGA TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
  • TABLE 125. SIGA TECHNOLOGIES, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 126. DYNAVAX TECHNOLOGIES CORPORATION: KEY EXECUTIVES
  • TABLE 127. DYNAVAX TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
  • TABLE 128. DYNAVAX TECHNOLOGIES CORPORATION: OPERATING SEGMENTS
  • TABLE 129. DYNAVAX TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
  • TABLE 130. DYNAVAX TECHNOLOGIES CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 131. ELUSYS THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 132. ELUSYS THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 133. ELUSYS THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 134. ELUSYS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 135. ELUSYS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 136. CLEVELAND BIOLABS: KEY EXECUTIVES
  • TABLE 137. CLEVELAND BIOLABS: COMPANY SNAPSHOT
  • TABLE 138. CLEVELAND BIOLABS: OPERATING SEGMENTS
  • TABLE 139. CLEVELAND BIOLABS: PRODUCT PORTFOLIO
  • TABLE 140. CLEVELAND BIOLABS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 141. ICHOR MEDICAL SYSTEMS: KEY EXECUTIVES
  • TABLE 142. ICHOR MEDICAL SYSTEMS: COMPANY SNAPSHOT
  • TABLE 143. ICHOR MEDICAL SYSTEMS: OPERATING SEGMENTS
  • TABLE 144. ICHOR MEDICAL SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 145. ICHOR MEDICAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 146. DYNPORT VACCINE COMPANY LLC: KEY EXECUTIVES
  • TABLE 147. DYNPORT VACCINE COMPANY LLC: COMPANY SNAPSHOT
  • TABLE 148. DYNPORT VACCINE COMPANY LLC: OPERATING SEGMENTS
  • TABLE 149. DYNPORT VACCINE COMPANY LLC: PRODUCT PORTFOLIO
  • TABLE 150. DYNPORT VACCINE COMPANY LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 151. ACHAOGEN, INC.: KEY EXECUTIVES
  • TABLE 152. ACHAOGEN, INC.: COMPANY SNAPSHOT
  • TABLE 153. ACHAOGEN, INC.: OPERATING SEGMENTS
  • TABLE 154. ACHAOGEN, INC.: PRODUCT PORTFOLIO
  • TABLE 155. ACHAOGEN, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 156. BAVARIAN NORDIC: KEY EXECUTIVES
  • TABLE 157. BAVARIAN NORDIC: COMPANY SNAPSHOT
  • TABLE 158. BAVARIAN NORDIC: OPERATING SEGMENTS
  • TABLE 159. BAVARIAN NORDIC: PRODUCT PORTFOLIO
  • TABLE 160. BAVARIAN NORDIC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 161. NANO THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 162. NANO THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 163. NANO THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 164. NANO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 165. NANO THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166. ALNYLAM PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 167. ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 168. ALNYLAM PHARMACEUTICALS, INC.: OPERATING SEGMENTS
  • TABLE 169. ALNYLAM PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 170. ALNYLAM PHARMACEUTICALS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • LIST OF FIGURES

  • FIGURE 1. GLOBAL BIO-DEFENSE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL BIO-DEFENSE MARKET
  • FIGURE 3. SEGMENTATION BIO-DEFENSE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN BIO-DEFENSE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALBIO-DEFENSE MARKET
  • FIGURE 11. BIO-DEFENSE MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. BIO-DEFENSE MARKET FOR ANTHRAX, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. BIO-DEFENSE MARKET FOR SMALL POX, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. BIO-DEFENSE MARKET FOR BOTULISM, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. BIO-DEFENSE MARKET FOR RADIATION/NUCLEAR, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. BIO-DEFENSE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. BIO-DEFENSE MARKET SEGMENTATION, BY BY APPLICATION
  • FIGURE 18. BIO-DEFENSE MARKET FOR MILITARY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. BIO-DEFENSE MARKET FOR CIVILIAN, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. BIO-DEFENSE MARKET SEGMENTATION, BY BY END USERS
  • FIGURE 21. BIO-DEFENSE MARKET FOR GOVERNMENT INSTITUTIONS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. BIO-DEFENSE MARKET FOR MILITARY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. BIO-DEFENSE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: BIO-DEFENSE MARKET
  • FIGURE 30. Top player positioning, 2022
  • FIGURE 31. EMERGENT BIO-SOLUTIONS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. EMERGENT BIO-SOLUTIONS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. EMERGENT BIO-SOLUTIONS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. XOMA CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. XOMA CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. XOMA CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. PHARMATHENE, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. PHARMATHENE, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. PHARMATHENE, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. SIGA TECHNOLOGIES, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. SIGA TECHNOLOGIES, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. SIGA TECHNOLOGIES, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. DYNAVAX TECHNOLOGIES CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. DYNAVAX TECHNOLOGIES CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. ELUSYS THERAPEUTICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. ELUSYS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. ELUSYS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. CLEVELAND BIOLABS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. CLEVELAND BIOLABS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. CLEVELAND BIOLABS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ICHOR MEDICAL SYSTEMS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ICHOR MEDICAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ICHOR MEDICAL SYSTEMS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. DYNPORT VACCINE COMPANY LLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. DYNPORT VACCINE COMPANY LLC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. DYNPORT VACCINE COMPANY LLC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. ACHAOGEN, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. ACHAOGEN, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. ACHAOGEN, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. BAVARIAN NORDIC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. BAVARIAN NORDIC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. BAVARIAN NORDIC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. NANO THERAPEUTICS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. NANO THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. NANO THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 67. ALNYLAM PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 68. ALNYLAM PHARMACEUTICALS, INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 69. ALNYLAM PHARMACEUTICALS, INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Bio-defense Market

Start reading.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers